Curcumin Analog CCA-1.1 Kills TNBC Cells in 3D Spheroid Culture

Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancers and remains one of the most difficult subtypes to treat, lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 targets. While chemotherapy remains the standard approach, researchers continue to explore natural compounds and their synthetic derivatives as potential adjuncts. Curcumin research has demonstrated preclinical anticancer activity across multiple cancer types, but its clinical utility is limited by poor bioavailability and rapid metabolism.

To overcome these limitations, scientists have developed synthetic curcumin derivatives designed to preserve anticancer activity while improving stability. One such compound is curcumin analog-1.1 (CCA-1.1), a monocarbonyl curcumin derivative. In a 2026 study published in the Asian Pacific Journal of Cancer Prevention, researchers evaluated CCA-1.1 using both traditional two-dimensional (2D) monolayer cultures and a more advanced 3D agarose-based spheroid system. The 3D model was chosen because it better mimics the tumor microenvironment, including cell-to-cell interactions and nutrient gradients that flat cultures cannot replicate.

Patients exploring natural compound approaches may find this line of research relevant, though it is critical to emphasize that no human clinical data exist for CCA-1.1. Those already working with a dosing calculator or established protocols should note that CCA-1.1 is not an available supplement and should not be confused with commercial curcumin products.

Table of Contents

• What Is CCA-1.1 and Why Test It in 3D?
• Key Findings from the 3D Spheroid Model
• Comparison with Doxorubicin and Clinical Implications
• Frequently Asked Questions

What Is CCA-1.1 and Why Test It in 3D?

CCA-1.1 is a synthetic curcumin derivative characterized by a modified monocarbonyl structure. Unlike natural curcumin, which degrades rapidly in physiological conditions, CCA-1.1 was designed to maintain chemical stability while retaining the core pharmacophore responsible for anticancer activity. The compound has been previously tested in 2D cultures, but the 2026 study represents the first evaluation in a 3D spheroid model for TNBC.

The 3D agarose-based spheroid system used in this study embeds MDA-MB-231 cells in a semi-solid matrix, allowing them to form spherical clusters that approximate the architecture of solid tumors. This approach has gained traction in preclinical research because drug responses in 3D models often differ significantly from 2D results, with many compounds showing reduced potency in 3D due to diffusion barriers, hypoxic cores, and altered gene expression patterns.

Key Findings from the 3D Spheroid Model

The researchers reported several quantitative findings:

• IC50 values: CCA-1.1 showed an IC50 of 1.48±0.28 µM in 2D cultures versus 6.12±0.27 µM in 3D spheroids. For comparison, the chemotherapy drug doxorubicin showed 0.79±0.22 µM (2D) and 2.65±0.3 µM (3D).
• Spheroid formation: CCA-1.1 reduced spheroid formation capacity by 40% compared to untreated controls, whereas doxorubicin achieved 96% inhibition.
• Structural integrity: Propidium iodide staining revealed that CCA-1.1 induced cell death while largely preserving spheroid architecture, unlike doxorubicin, which caused structural disruption.
• EMT markers: Gene expression analysis showed alterations in epithelial-mesenchymal transition markers, including E-cadherin, MMP2, and MMP9, suggesting that CCA-1.1 may influence metastasis-related pathways.

The higher IC50 in 3D versus 2D is a clinically relevant observation. It suggests that compounds tested only in flat cultures may overestimate their therapeutic potential, reinforcing the importance of more realistic preclinical models.

Comparison with Doxorubicin and Clinical Implications

Doxorubicin, a standard anthracycline chemotherapy, outperformed CCA-1.1 in both potency and spheroid inhibition in this study. However, the researchers noted that CCA-1.1's preservation of spheroid structure while selectively killing cancer cells could indicate a different mechanism of action—one that might be exploitable in combination strategies rather than as a standalone replacement for chemotherapy.

The altered EMT marker expression is particularly noteworthy. MMP2 and MMP9 are matrix metalloproteinases associated with invasion and metastasis. Any compound that modulates these markers without the severe cytotoxicity of conventional chemotherapy warrants further investigation, though it remains years away from clinical application.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested curcumin for researchers exploring repurposed antioxidant anticancer strategies.

Disclaimer: Links are informational and do not constitute medical advice. Always consult a healthcare provider before using any supplement or medication.

References

1. PMID 42522831: Agarose-Based 3D Spheroid Model to Evaluate the Anticancer Activity of the Curcumin Analog CCA-1.1 in Triple-Negative Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2026.
2. Curcumin and Cancer: What Human and Preclinical Research Actually Shows — Sanare Lab long-read.